Download Files:
AZ3391
$460 – $3,850
Products Details
Product Description
– AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23)[1].
Web ID
– HY-144874
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C23H27FN6O2
References
– [1]Martin John Packer, et al. Quinoxaline derivatives as anti-cancer drugs. Patent WO2021260092A1.
CAS Number
– 2756333-42-1
Molecular Weight
– 438.50
Compound Purity
– 98.03
SMILES
– O=C(C1=NC(C)=C(N2CCN(CC3=C(F)C4=C(N=C(CC)C(N4)=O)C=C3)CC2)C=C1)NC
Clinical Information
– No Development Reported
Research Area
– Cancer; Neurological Disease
Solubility
– DMSO : 16.67 mg/mL (ultrasonic)
Target
– PARP
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
